指南与共识治疗药物监测与药物基因组学药物不良反应与药物警戒

ABC基因多态性对卡培他滨药动学与药效学的影响:剂量推荐意义

Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations.
指南 / 共识 · Br J Clin Pharmacol · 2020-07-08

模型显示rs6720173和rs2271862分别增加5'-DFUR和5-FU清除率,奥沙利铂联用使药效斜率增加2.84倍,并据此提出基于基因型和联合方案的剂量推荐。

要点

  • rs6720173突变使5'-DFUR清除率增加182%,rs2271862突变使5-FU清除率增加184%。
  • 联用奥沙利铂使药效斜率增加2.84倍,G3/4中性粒细胞减少暴露阈值联合组26 mg·h/L、单药组70 mg·h/L。
  • 基于rs2271862突变与否提出单药和联合奥沙利铂的卡培他滨剂量上限推荐。

核心结论

  • 群体药动学/药效学模型可刻画结直肠癌患者卡培他滨及其代谢物的血浆时间过程。
  • 基于ABC基因SNP rs2271862和是否联用奥沙利铂,提出了卡培他滨的剂量推荐。

研究设计与样本

  • 共采集432个卡培他滨、5'-DFUR和5-FU血浆浓度,以及370个中性粒细胞观测。
  • 血浆浓度于给药后1、2、3小时测定,中性粒细胞于给药后第15至24天测定。

主要发现

  • 药动学模型纳入奥沙利铂对吸收滞后时间的影响、rs6720173对5'-DFUR清除率的影响(突变型增加182%)和rs2271862对5-FU清除率的影响(突变型增加184%)。
  • 系统相关参数为Circ0=3.54×10^9 cells/mL、MTT=204小时、γ=6.0×10^-2;药物相关斜率SLP=3.1×10^-2 mL/mg。
  • 联用奥沙利铂使SLP增加2.84倍。
  • 预测G3/4中性粒细胞减少的暴露阈值在联合治疗为26 mg·h/L,单药治疗为70 mg·h/L。

关键数值与推荐

  • 对于rs2271862突变等位基因患者,单药治疗卡培他滨剂量推荐≤3000 mg/m2/24 h,联合奥沙利铂时≤1750 mg/m2/24 h。
  • 对于rs2271862野生型等位基因患者,单药治疗卡培他滨剂量推荐≤2400 mg/m2/24 h,联合奥沙利铂时≤600 mg/m2/24 h。

临床怎么用

  • 临床可参考rs2271862基因型及是否联用奥沙利铂,确定卡培他滨的剂量上限。
  • 联合奥沙利铂时需关注中性粒细胞减少风险,暴露阈值低于单药治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims are to develop a population pharmacokinetic model of capecitabine (CAP) and its main metabolites after the oral administration of CAP in colorectal cancer patients with different polymorphisms of the ATP-binding cassette (ABC) gene and a population pharmacokinetic/pharmacodynamic model capable of accounting for the neutropenic effects, and to optimize the dosing strategy based on the polymorphisms of the ABC gene and/or the administration regimen as a single agent or in combination. METHODS: Forty-eight patients diagnosed with colorectal cancer were included, with 432 plasma levels of CAP, 5'-desoxi-5-fluorouridine (5'-DFUR) and 5-fluorouracil (5-FU), and 370 neutrophil observations. Capecitabine doses ranged from 1250 to 2500 mg/m2 /24 h. Plasma measurements of CAP, 5'-DFUR and 5-FU were obtained at 1, 2 and 3 hours post administration. Neutrophil levels were measured between day 15 and day 24 post administration. RESULTS: The pharmacokinetic model incorporates oxaliplatin as a covariate on absorption lag time, rs6720173 (ABCG5 gene) on clearance of 5'-DFUR (182% increase for mutated rs6720173) and rs2271862 (ABCA2 gene) on clearance of 5-FU (184% increase for mutated rs2271862). System- (Circ0 = 3.54 × 109 cells/mL, MTT = 204 hours and γ = 6.0 × 10-2 ) and drug-related (slope [SLP] = 3.1 × 10-2 mL/mg). Co-administration of oxaliplatin resulted in a 2.84-fold increase in SLP. The predicted exposure thresholds to G3/4 neutropenia in combination and monotherapy were 26 and 70 mg·h/L, respectively. CONCLUSIONS: The population pharmacokinetic/pharmacodynamic model characterized the time course of capecitabine and its metabolites in plasma. Dose recommendations of capecitabine in patients with mutated and wild allele for single nucleotide polymorphisms rs2271862 of ≤3000 and ≤2400 mg/m2 /24 h in monotherapy and ≤1750 and ≤600 mg/m2 /24 h in combination with oxaliplatin, respectively, have been proposed.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sáez-Belló M, Mangas-Sanjuán V, Martínez-Gómez MA, et al. Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. Br J Clin Pharmacol. 2020. PMID: 32559325. doi:10.1111/bcp.14441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。